Glioblastoma Multiforme Market Report 2026

Glioblastoma Multiforme Market Overview

• Glioblastoma Multiforme market size has reached to $2.7 billion in 2025 • Expected to grow to $3.94 billion in 2030 at a compound annual growth rate (CAGR) of 7.8% • Growth Driver: Impact Of Rising Brain Disorder Cases On The Market Growth • Market Trend: Advancements In CAR T-Cell Therapies For Glioblastoma Multiforme Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Glioblastoma Multiforme Market?

Glioblastoma multiforme (GBM) is an aggressive and fast-growing brain tumor that originates in the glial cells of the brain. It is the lethal form of primary brain cancer, characterized by rapid proliferation and resistance to standard treatments. The main types of drug classes for glioblastoma multiforme are chemotherapy agents, temozolomide, carmustine, lomustine, and others. Chemotherapy agents for glioblastoma multiforme target and disrupt cancer cell division, helping control tumor growth and improve survival, often in combination with other treatments. It is diagnosed by various diagnostic tools such as magnetic resonance imaging (MRI), computed tomography scan (CT scan), biopsy, and others and treated with several treatment types, including surgery, radiation therapy, chemotherapy, immunotherapy, tumor treating field therapy, and others. It is used by various end-users, such as hospitals, cancer research institutes, ambulatory surgical centers, and others.

What Is The Glioblastoma Multiforme Market Growth Forecast?

The glioblastoma multiforme market size is expected to see strong growth in the next few years. It will grow to $3.94 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to development of novel targeted drugs, expansion of immunotherapy research, personalized cancer treatment adoption, increased funding for brain cancer research, improved survival outcome focus. Major trends in the forecast period include increased focus on targeted cancer therapies, rising use of multimodal treatment approaches, expansion of precision oncology research, growing adoption of advanced imaging diagnostics, improved clinical trial participation.

Global Glioblastoma Multiforme Market Segmentation

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes 2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools 3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types 4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users Subsegments: 1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites 2) By Temozolomide: Branded (Temodar), Generic Temozolomide 3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel) 4) By Lomustine: Branded (Gleostine), Generic Lomustine 5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

What Is The Driver Of The Glioblastoma Multiforme Market?

The rising brain disorder cases are expected to drive the glioblastoma multiforme market going forward. A brain disorder is a condition that affects the structure or function of the brain, leading to cognitive, emotional, or physical impairments. Rising brain disorder cases are due to factors such as aging populations, increased life expectancy, lifestyle factors, and improved diagnostic capabilities. Understanding brain disorders helps advance research on glioblastoma multiforme (GBM), leading to better early detection, innovative treatments, and improved patient outcomes. By studying neurological conditions, scientists can uncover genetic and molecular links that contribute to GBM development. For instance, in February 2025, according to Dementia Australia, an Australia-based non-profit organization, approximately 433,300 Australians are living with dementia, with this number expected to rise to 812,500 by 2054. Additionally, younger-onset dementia affects around 29,000 people in 2025, with projections indicating an increase to 41,000 by 2054. Therefore, the rising brain disorder cases will drive the growth of the glioblastoma multiforme industry.

Key Players In The Global Glioblastoma Multiforme Market

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

Global Glioblastoma Multiforme Market Trends and Insights

Major companies operating in the glioblastoma multiforme market are focusing on developing advanced therapies, such as CAR T-cell therapies, to address the unmet medical needs of aggressive cancer. CAR T-cell therapies are a form of immunotherapy that involves modifying a patient's T-cells to target and kill cancer cells more effectively. For instance, in June 2023, Chimeric Therapeutics Limited, an Australia-based biotech company, launched a Phase IB clinical trial of CHM 1101 (CLXT CAR T) therapy for recurrent or progressive glioblastoma multiforme (GBM). The trial, conducted at multiple centers, aims to evaluate the therapy's safety and efficacy while determining the recommended Phase 2 dose. Initial Phase 1a results showed disease stability, and the trial will build on this to support further development. The company plans to use the data to design a registration trial and seek regulatory feedback.

What Are Latest Mergers And Acquisitions In The Glioblastoma Multiforme Market?

In October 2024, Merck & Co., a US-based pharmaceutical company specializing in prescription medicines and vaccines, acquired Modifi Biosciences for an undisclosed amount. Through this acquisition, Merck aims to advance its oncology pipeline by integrating Modifi’s preclinical small-molecule platform, which targets cancer cells with defects in deoxyribonucleic acid (DNA) repair, including those lacking the O6-methylguanine-DNA methyltransferase (MGMT) protein, and shows potential against highly refractory tumors such as glioblastoma. Modifi Biosciences Inc. is a US-based company that provides a treatment targeting Glioblastoma Multiforme (GBM).

Regional Outlook

North America was the largest region in the glioblastoma multiforme market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Glioblastoma Multiforme Market?

The glioblastoma multiforme market consists of revenues earned by entities by providing services such as palliative care, psychosocial support, and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The glioblastoma multiforme market also includes sales of drugs, diagnostic tools, personalized medicine, and advanced drug delivery systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Glioblastoma Multiforme Market Report 2026?

The glioblastoma multiforme market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glioblastoma multiforme industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.